Boston Scientific Corporation
Boston Scientific Corporation (0HOY.L) Financial Performance & Income Statement Overview
Analyze Boston Scientific Corporation (0HOY.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Boston Scientific Corporation (0HOY.L) Income Statement & Financial Overview
View the income breakdown for Boston Scientific Corporation 0HOY.L across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $4.66B | $4.56B | $4.21B | $4.12B |
| Cost of Revenue | $1.45B | $1.47B | $1.31B | $1.27B |
| Gross Profit | $3.21B | $3.10B | $2.90B | $2.85B |
| Gross Profit Ratio | $0.69 | $0.68 | $0.69 | $0.69 |
| R&D Expenses | $443.00M | $459.00M | $407.00M | $383.00M |
| SG&A Expenses | $1.60B | $1.61B | $1.56B | $1.45B |
| Operating Expenses | $2.29B | $2.42B | $2.16B | $2.33B |
| Total Costs & Expenses | $3.74B | $3.89B | $3.48B | $3.60B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $82.00M | $80.00M | $79.00M | $77.00M |
| Depreciation & Amortization | $325.00M | $348.00M | $306.00M | $311.00M |
| EBITDA | $1.21B | $1.01B | $1.05B | $812.00M |
| EBITDA Ratio | $0.26 | $0.22 | $0.25 | $0.20 |
| Operating Income | $921.00M | $675.00M | $733.00M | $520.00M |
| Operating Income Ratio | $0.20 | $0.15 | $0.17 | $0.13 |
| Other Income/Expenses (Net) | -$116.00M | -$90.00M | -$64.00M | -$100.00M |
| Income Before Tax | $805.00M | $585.00M | $669.00M | $420.00M |
| Income Before Tax Ratio | $0.17 | $0.13 | $0.16 | $0.10 |
| Income Tax Expense | $133.00M | $23.00M | $200.00M | $98.00M |
| Net Income | $674.00M | $566.00M | $468.00M | $324.00M |
| Net Income Ratio | $0.14 | $0.12 | $0.11 | $0.08 |
| EPS | $0.46 | $0.38 | $0.32 | $0.22 |
| Diluted EPS | $0.45 | $0.38 | $0.32 | $0.22 |
| Weighted Avg Shares Outstanding | $1.48B | $1.47B | $1.47B | $1.47B |
| Weighted Avg Shares Outstanding (Diluted) | $1.49B | $1.49B | $1.49B | $1.48B |
Over the last four quarters, Boston Scientific Corporation's revenue moved from $4.12B in Q2 2024 to $4.66B in Q1 2025. Operating income in Q1 2025 was $921.00M, with a strong operating margin of 20%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Boston Scientific Corporation remained robust at $1.21B, reflecting operational efficiency. Net income rose to $674.00M, with an EPS of $0.46. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan